FrancophonIA/ELRC3.0 huggingface dataset:
English: CI = confidence interval; DOR = duration of response; OS = overall survival.
Slovenian: IZ = interval zaupanja; DOR (duration of response) = trajanje odgovora; OS (overall survival) = celokupno preživetje.
English: In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section
Slovenian: Pri bolnikih z EGFR mutiranim ali ALK pozitivnim NDRP je zdravilo Tecentriq v kombinaciji z bevacizumabom, paklitakselom in karboplatinom indicirano le, ko so izčrpana ustrezna tarčna zdravljenja (glejte poglavje 5.1).
English: Table 11: Intravenous treatment regimens (IMpower133) Treatment regimen
Slovenian: Intravenske sheme zdravljenja (IMpower133) Shema zdravljenja
English: In Cohort 2, the co-primary efficacy endpoints were confirmed ORR as assessed by an IRF using RECIST v1.1 and investigator-assessed ORR according to Modified RECIST (mRECIST) criteria.
Slovenian: V 2. kohorti so bili soprimarni opazovani dogodki učinkovitosti potrjen delež objektivnega odgovora po oceni IRF z uporabo meril RECIST v1.1 in delež objektivnega odgovora po oceni raziskovalca glede na spremenjena merila RECIST (mRECIST).
English: One patient required the use of corticosteroids and treatment with atezolizumab was discontinued.
Slovenian: En bolnik je potreboval kortikosteroide in je prenehal z zdravljenjem z atezolizumabom.
English: If symptoms improve to ≤ Grade 1, taper corticosteroids as clinically indicated.
Slovenian: Če se simptomi izboljšajo na ≤ 1. stopnjo, je treba odmerek kortikosteroidov zmanjšati, kot je klinično indicirano.
English: The median time to onset was 7.7 months (range: 5.0 to 8.8 months).
Slovenian: Mediani čas do pojava je bil 7,7 meseca (razpon: od 5,0 do 8,8 meseca).
English: # Primary efficacy endpoints were PFS and OS and they were analysed in the ITT-wild-type (WT) population,
Slovenian: Mediana v mesecih 95-% IZ Primarna opazovana dogodka učinkovitosti sta bila PFS in OS; analizirana sta bila v populaciji ITT-divji-tip, t.j.
English: At the time of the final analysis for PFS, patients had a median follow up time of 15.3 months.
Slovenian: Ob času končne analize preživetja brez napredovanja bolezni (PFS) je mediano spremljanje bolnikov trajalo 15,3 meseca.
English: Note: Toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Event Version 4.0 (NCI-CTCAE v.4.
Slovenian: Opomba: Stopnje toksičnosti so navedene po merilih NCI-CTCAE V.4 (National Cancer Institute Common
English: Diabetes mellitus led to the discontinuation of atezolizumab in < 0.1% (3/3,178) patients.
Slovenian: Zaradi sladkorne bolezni je atezolizumab prenehalo uporabljati < 0,1 % (3/3178) bolnikov.
English: Figure 5: Kaplan-Meier Curve for Overall Survival in patients with PD-L1 expression ≥ 1% (IMpassion130)
Slovenian: Slika 5: Kaplan-Meierjeva krivulja celokupnega preživetja pri bolnikih z izražanjem PD-L1 ≥ 1 % (IMpassion130)
English: Only a few patients had severe renal impairment (eGFR 15 to 29 mL/min/1.73 m2; n=8) (see section 4.2).
Slovenian: 29 ml/min/1,73 m2) je imelo le malo bolnikov (n = 8) (glejte poglavje 4.2).
English: • inflammation or problems of the nerves (neuropathy): symptoms may include muscle weakness and numbness, tingling in hands and feet
Slovenian: • vnetje ali motnje živcev (nevropatija): med simptomi so lahko mišična šibkost in omrtvičenost ali mravljinčenje v dlaneh in stopalih;
English: Figure 1: Kaplan-Meier curve for overall survival (IMvigor211)
Slovenian: Slika 1: Kaplan-Meierjeva krivulja celokupnega preživetja (IMvigor211)
English: Per the pre-specified hierarchical testing order, the IC2/3 population was tested first, with an OS HR of 0.87 (95% CI: 0.63, 1.21; median OS of 11.1 vs. 10.6 months for atezolizumab and chemotherapy respectively).
Slovenian: Glede na vnaprej določeno hierarhično testiranje so populacijo IC2/3 testirali najprej z razmerjem ogroženosti za celokupno preživetje 0,87 (95-% IZ: 0,63; 1,21; mediano celokupno preživetje 11,1 meseca za atezolizumab v primerjavi z 10,6 meseca za kemoterapijo).
English: q Includes reports of pneumonitis, lung infiltration, bronchiolitis, interstitial lung disease, radiation pneumonitis.
Slovenian: Vključuje poročila o pnevmonitisu, infiltraciji pljuč, bronhiolitisu, intersticijski bolezni pljuč, radiacijskem pnevmonitisu.
English: The median age was 64 years (range: 26 to 90 years) with 10% of patients ≥75 years of age.
Slovenian: Mediana starost je bila 64 let (razpon: od 26 do 90 let) in 10 % bolnikov je bilo starih ≥ 75 let.
English: Treatment with atezolizumab may be resumed when symptoms are controlled and thyroid function is improving.
Slovenian: Zdravljenje z atezolizumabom se lahko znova začne, ko so simptomi obvladani in se delovanje ščitnice izboljšuje.
English: Table 6: Summary of updated efficacy in the ITT population (IMpower150) Efficacy endpoint
Slovenian: Povzetek posodobljenih podatkov o učinkovitosti v populaciji ITT (IMpower150) Opazovani dogodek učinkovitosti
English: 22.9 months), the median OS for both arms was unchanged relative to the primary OS interim analysis.
Slovenian: V eksploratorni končni analizi OS z daljšim spremljanjem (mediana: 22,9 meseca) je bilo mediano OS za obe skupini glede na vmesno primarno analizo OS nespremenjeno.
English: Tecentriq used in combination with anticancer medicines The following side effects have been reported in clinical trials when Tecentriq is given in combination with anticancer medicines:
Slovenian: Uporaba zdravila Tecentriq v kombinaciji z zdravili proti raku Ko so v kliničnih preskušanjih uporabljali zdravilo Tecentriq v kombinaciji z drugimi zdravili proti raku, so poročali o naslednjih neželenih učinkih:
English: 89 mL/min/1.73 m2; n=208) or, moderate (eGFR 30 to 59 mL/min/1.73 m2; n=116) renal impairment compared to patients with normal (eGFR greater than or equal to 90 mL/min/1.73 m2; n=140) renal function.
Slovenian: ali zmerno (eGFR 30 do 59 ml/min/1,73 m 2; n = 116) okvaro ledvic in bolnikih z normalnim delovanjem ledvic (eGFR ≥ 90 ml/min/1,73 m 2; n = 140).
English: The median age was 67 years (range: 31 to 88), and 77.1% of patients were male.
Slovenian: Mediana starost je bila 67 let (razpon: 31 do 88) in 77,1% bolnikov je bilo moških.
English: IMvigor130 (WO30070): Phase III multi-center, randomized, placebo-controlled study of atezolizumab as monotherapy and in combination with platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma
Slovenian: IMvigor130 (WO30070): Multicentrična, randomizirana, s placebom primerjana študija faze III atezolizumaba v monoterapiji in kombinaciji s kemoterapijo na osnovi platine pri bolnikih z nezdravljenim, lokalno napredovalim ali razsejanim urotelijskim karcinomom
English: Guillain-Barré syndrome led to discontinuation of atezolizumab in 1 patient (< 0.1%).
Slovenian: Zaradi Guillain-Barréjevega sindroma je zdravljenje z atezolizumabom prenehal 1 bolnik (< 0,1 %).
English: Patients with ES-SCLC were treated with atezolizumab until disease progression.
Slovenian: Bolnike z razsejanim DRP so zdravili z atezolizumabom do napredovanja bolezni.
English: Patients receiving treatment regimen B were able to crossover and receive atezolizumab monotherapy following disease progression.
Slovenian: Bolniki, ki so prejemali terapevtsko shemo B, so lahko po napredovanju bolezni navzkrižno prešli na prejemanje monoterapije z atezolizumabom.
English: Diabetes mellitus
Slovenian: Sladkorna bolezen
English: Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).
Slovenian: Zdravilo Tecentriq je v kombinaciji z nab-paklitakselom in karboplatinom indicirano kot prva linija zdravljenja odraslih bolnikov z razsejanim neploščatoceličnim NDRP, ki ni EGFR mutiran ali ALK pozitiven (glejte poglavje 5.1).
English: The median DOR was not reached in any PD-L1 expression subgroup or in all comers.
Slovenian: Mediano trajanje odgovora ni bilo doseženo ne v kateri od podskupin izražanja PD-L1 ne med neselekcioniranimi bolniki.
English: The most common adverse reactions (≥ 20%) were nausea (37.4%), fatigue (36.4%), neutropenia (33.7%), anaemia (33.2%), diarrhoea (29.5%), rash (28.5%), constipation (27.0%), peripheral neuropathy (26.8%), decreased appetite (24.6%), thrombocytopenia (21.2%) and cough (20.1%).
Slovenian: Najpogostejši neželeni učinki (≥ 20 %) so bili navzea (37,4 %), utrujenost (36,4 %), nevtropenija (33,7 %), anemija (33,2 %), diareja (29,5 %), izpuščaj (28,5 %), zaprtost (27,0 %), periferna nevropatija (26,8 %), zmanjšan apetit (24,6 %), trombocitopenija (21,2 %) in kašelj (20,1 %).
English: Includes reports of cytokine release syndrome, hypersensitivity, anaphylaxis.
Slovenian: Vključuje poročila o sindromu sproščanja citokinov, preobčutljivosti, anafilaksiji.
English: Based on the severity of the adverse reaction, atezolizumab should be withheld and corticosteroids administered.
Slovenian: Glede na izrazitost neželenega učinka je treba uporabo atezolizumaba odložiti in uvesti kortikosteroide.
English: • low platelet count, which may make you more likely to bruise or bleed
Slovenian: • majhno število trombocitov, zaradi česar ste lahko bolj nagnjeni k podplutbam ali krvavitvam
English: Investigator-assessed confirmed DOR (RECIST 1.1)^
Slovenian: Potrjeno DOR po oceni raziskovalca (RECIST 1.1)^
English: Based on a population pharmacokinetic analysis, no dose adjustment is required in patients with mild or moderate renal impairment (see section 5.2).
Slovenian: Glede na populacijsko farmakokinetično analizo bolnikom z blago ali zmerno okvaro ledvic odmerka ni treba prilagoditi (glejte poglavje 5.2).
English: The median time to onset was 4.9 months (range: 0 day to 31.3 months).
Slovenian: Mediani čas do pojava je bil 4,9 meseca (razpon: od 0 dni do 31,3 meseca).
English: Treatment may be resumed when symptoms are controlled by thyroid replacement therapy and TSH levels are decreasing
Slovenian: Zdravljenje se lahko znova začne, ko so simptomi obvladani z nadomestnim zdravljenjem s ščitničnimi hormoni in se koncentracija TSH znižuje.
English: The median time to onset was 3.4 months (range 3 days to 24.8 months).
Slovenian: Mediani čas do pojava je bil 3,4 meseca (razpon: od 3 dni do 24,8 meseca).
English: Tecentriq is an anti-cancer medicine that contains the active substance atezolizumab.
Slovenian: Zdravilo Tecentriq je zdravilo za zdravljenje rakavih obolenj, ki vsebuje učinkovino atezolizumab.
English: Stratified hazard ratio
Slovenian: Stratificirano razmerje ogroženosti
English: Immune-related meningoencephalitis
Slovenian: Imunsko pogojeni meningoencefalitis
English: If particulates or discoloration are observed, the solution should not be used.
Slovenian: Če opazite, da je raztopina spremenjene barve ali da so v njej delci, je ne smete uporabiti.
English: 2,759 patients across multiple tumour types.
Slovenian: Varnost atezolizumaba v kombinaciji z drugimi učinkovinami so ocenili pri 2759 bolnikih z različnimi vrstami tumorjev.
English: Patients should be closely monitored for signs and symptoms that are suggestive of acute pancreatitis.
Slovenian: Bolnike je treba nadzorovati glede znakov in simptomov, ki kažejo na akutni pankreatitis.
English: z Includes reports of proteinuria, protein urine present, haemoglobinurea, nephrotic syndrome.
Slovenian: Vključuje poročila o proteinuriji, prisotnosti beljakovin v urinu, hemoglobinuriji, nefrotskem sindromu.
English: Treatment with atezolizumab should be permanently discontinued for Grade 4 or grade 3 recurrent myositis, or when unable to reduce the corticosteroid dose to the equivalent of ≤ 10 mg prednisone per day within 12 weeks after onset.
Slovenian: Zdravljenje z atezolizumabom je treba trajno ukiniti v primeru miozitisa 4. stopnje ali ponovljenega miozitisa 3. stopnje ali kadar ni mogoče zmanjšati odmerka kortikosteroidov na ekvivalent ≤ 10 mg prednizona na dan v 12 tednih od začetka zdravljenja.
English: Patients with Grade 1 or 2 infusion-related reactions may continue to receive atezolizumab with close monitoring; premedication with antipyretic and antihistamines may be considered.
Slovenian: Bolniki, ki imajo z infundiranjem povezane reakcije 1. ali 2. stopnje, lahko še naprej prejemajo atezolizumab pod natančnim nadzorom;
English: The median time to onset was 13.1 months (range: 9.0 to 17.5 months).
Slovenian: Mediani čas do pojava je bil 13,1 meseca (razpon: od 9,0 do 17,5 meseca).
English: How much Tecentriq is given
Slovenian: Koliko zdravila Tecentriq boste dobili
English: Maintenance (21-Day Cycles)
Slovenian: Vzdrževanje (21-dnevni cikli)
English: • inflammation of the thyroid, adrenal glands and the pituitary gland (hypothyroidism, hyperthyroidism, adrenal insufficiency or hypophysitis): symptoms may include tiredness, weight loss, weight gain, change in mood, hair loss, constipation, dizziness, headaches, increased thirst, increased urination and changes in vision.
Slovenian: • vnetje ščitnice, nadledvičnih žlez in hipofize (premajhno delovanje žleze ščitnice (hipotiroidizem), prekomerno delovanje žleze ščitnice (hipertiroidizem), poslabšanje delovanja nadledvičnih žlez ali vnetje hipofize (hipofizitis)): med simptomi so lahko utrujenost, hujšanje, povečanje telesne mase, spremembe razpoloženja, izpadanje las; zaprtost, omotica, glavoboli, povečana žeja, povečano odvajanje urina in spremembe vida;
English: Pancreatitis, including amylase increased and lipase increased, occurred in 0.6% (18/3,178) of patients who received atezolizumab monotherapy.
Slovenian: Pankreatitis, vključno z zvišanjem amilaze in zvišanjem lipaze, se je pojavil pri 0,6 % (18/3178) bolnikov, ki so prejemali atezolizumab v monoterapiji.
English: Hyperthyroidism:
Slovenian: Hipertiroidizem
English: Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see section 5.1).
Slovenian: Zdravilo Tecentriq je v kombinaciji s karboplatinom in etopozidom indicirano kot prva linija zdravljenja odraslih bolnikov z razsejanim drobnoceličnim rakom pljuč (DRP) (glejte poglavje 5.1).
English: Data for patients ≥ 75 years of age are too limited to draw conclusions on this population.
Slovenian: Za bolnike, stare ≥ 75 let, je podatkov premalo, da bi navedli zaključke o tej populaciji.
English: AST increased, ALT increased, hepatitisv
Slovenian: hepatitisv zvišanje AST, zvišanje ALT
English: Fourteen point seven percent of patients had liver metastases at baseline, and most patients were current or previous smokers (90%).
Slovenian: Štirinajst celih sedem odstotka (14,7 %) bolnikov je imelo izhodiščno zasevke v jetrih in večina bolnikov je bila sedanjih ali nekdanjih kadilcev (90 %).
English: The median time to onset was 3.6 months (range 3 days to 9.9 months).
Slovenian: Mediani čas do pojava je bil 3,6 mesece (razpon: od 3 dni do 9,9 meseca.
English: • inflammation of the heart muscle (myocarditis): symptoms may include shortness of breath, decreased exercise tolerance, feeling tired, chest pain, swelling of the ankles or legs, irregular heartbeat, and fainting
Slovenian: • vnetje srčne mišice (miokarditis): med simptomi so lahko težko dihanje, zmanjšanje tolerance za vadbo, utrujenost, bolečina v prsih, otekanje gležnjev ali nog, neredno bitje srca, omedlevica;
English: • overactive thyroid gland (hyperthyroidism)
Slovenian: • prekomerno delovanje žleze ščitnice (hipertiroidizem)
English: Tlf: +47 - 22 78 90 00
Slovenian: Roche Norge AS Tlf: +47 - 22 78 90 00
English: Figure 7: Forest plot of overall survival by PD-L1 expression (IMpower130)
Slovenian: Slika 7: Drevesni diagram celokupnega preživetja glede na izražanje PD-L1 (IMpower130)
English: The key results in the all comer population are summarised in Table 3.
Slovenian: Ključni rezultati v populaciji neselekcioniranih bolnikov so povzeti v preglednici 3.
English: Patients with locally advanced or metastatic UC who are ineligible for cisplatin therapy were treated with atezolizumab until disease progression.
Slovenian: Bolnike z lokalno napredovalim ali razsejanim urotelijskim karcinomom, neprimerne za zdravljenje s cisplatinom, so zdravili z atezolizumabom do napredovanja bolezni.
English: No developmental and reproductive studies were conducted with atezolizumab.
Slovenian: Študij razvoja in reproduktivnih študij z atezolizumabom niso izvedli.
English: Includes report of nephritis, Henoch-Schonlein Purpura nephritis.
Slovenian: aa Vključuje poročilo o nefritisu, nefritisu zaradi Henoch-Schönleinove purpure.
English: However, patients with EGFR mutations did not show improved OS with atezolizumab compared to docetaxel (HR of 1.24, 95% CI: 0.71, 2.18; median OS of 10.5 vs. 16.2 months for atezolizumab and docetaxel, respectively).
Slovenian: A pri bolnikih, ki so imeli mutacije EGFR, se celokupno preživetje z atezolizumabom v primerjavi z docetakselom ni izboljšalo (RO 1,24; 95-% IZ: 0,71, 2,18; mediano 10,5 meseca z atezolizumabom in 16,2 meseca z docetakselom).
English: IMvigor210 (GO29293): Single-arm trial in previously untreated urothelial carcinoma patients who are ineligible for cisplatin therapy and in urothelial carcinoma patients previously treated with chemotherapy
Slovenian: IMvigor210 (GO29293): Preskušanje z eno skupino pri bolnikih s predhodno nezdravljenim urotelijskim karcinomom, ki za zdravljenje s cisplatinom niso primerni, in pri bolnikih z urotelijskim karcinomom, ki so bili predhodno zdravljeni s kemoterapijo
English: Figure 4: Kaplan-Meier Curve for Progression Free Survival in patients with PD-L1 expression ≥ 1% (IMpassion130)
Slovenian: Slika 4: Kaplan-Meierjeva krivulja preživetja brez napredovanja bolezni pri bolnikih z izražanjem PD-L1 ≥ 1 % (IMpassion130)
English: If you have not received anticancer medicines before for advanced lung cancer, Tecentriq will be given to you in combination with or without bevacizumab and anticancer medicines (chemotherapies called carboplatin and paclitaxel or nab paclitaxel).
Slovenian: Če za zdravljenje napredovalega raka pljuč predhodno še niste prejeli zdravil proti raku, boste zdravilo Tecentriq prejeli v kombinaciji z bevacizumabom ali brez njega in še dvema zdraviloma proti raku
English: Myasthenic syndrome
Slovenian: Miastenijski sindrom
English: There is no information on overdose with atezolizumab.
Slovenian: Informacij o prevelikem odmerjanju atezolizumaba ni.
English: The median time to onset was 5.5 months (range: 3 days to 19 months).
Slovenian: Mediani čas do pojava je bil 5,5 meseca (razpon: od 3 dni do 19 mesecev).
English: Parenteral medicinal products should be inspected visually for particulates and discolouration prior to administration.
Slovenian: Zdravila za parenteralno uporabo je treba pred uporabo pregledati glede prisotnosti delcev in spremembe barve.
English: Grade 3 or 4: (creatinine level > 3.0 x baseline or > 3.0 x ULN)
Slovenian: 3. ali 4. stopnja: koncentracija kreatinina > 3,0-kratna izhodiščna vrednost ali > 3,0-kratna ZNM)
English: Thyroid function should be monitored prior to and periodically during treatment with atezolizumab.
Slovenian: Delovanje ščitnice je treba spremljati pred zdravljenjem z atezolizumabom in redno med zdravljenjem.
English: and 0.82 for OS while in patients who had not received prior (neo)adjuvant treatment (n=127), the hazard ratio for PFS was 0.44 and 0.53 for OS.
Slovenian: Pri bolnikih, ki so prejemali predhodno (neo)adjuvantno zdravljenje (n = 242), je bilo razmerje ogroženosti za PFS 0,79 in za OS 0,8; pri bolnikih, ki niso prejeli predhodnega (neo)adjuvantnega zdravljenja (n = 127), je bilo razmerje ogroženosti za PFS 0,44 in za OS 0,53.
English: No dedicated studies of atezolizumab have been conducted in elderly patients.
Slovenian: Namenskih študij z atezolizumabom pri starejših bolnikih niso izvedli.
English: The median time to onset was 15 days (range: 0 day to 12.5 months).
Slovenian: Mediani čas do pojava je bil 15 dni (razpon: od 0 dni do 12,5 meseca).
English: A statistically significant improvement in OS was observed with atezolizumab in combination with carboplatin and etoposide compared to the control arm (HR of 0.70, 95% CI: 0.54, 0.91; median OS of 12.3 months vs. 10.3 months).
Slovenian: Za kombinacijo atezolizumaba s karboplatinom in etopozidom so glede na primerjalno skupino opazili statistično značilno izboljšanje celokupnega preživetja (RO 0,70, 95-% IZ: 0,54, 0,91; mediano OS 12,3 meseca v primerjavi z 10,3 meseca).
English: The recommended dose of Tecentriq is 1,200 mg administered intravenously every three weeks.
Slovenian: Priporočeni odmerek zdravila Tecentriq je 1200 mg intravensko na vsake tri tedne.
English: A phase II, multi-centre, international, randomised, open-label, controlled study, POPLAR, was conducted in patients with locally advanced or metastatic NSCLC who progressed during or following a platinum-containing regimen, regardless of PD-L1 expression.
Slovenian: Multicentrično, mednarodno, randomizirano, odprto, kontrolirano študijo faze II (POPLAR) so izvedli pri bolnikih z lokalno napredovalim ali razsejanim NDRP (ne glede na izražanje PD-L1), ki jim je bolezen napredovala med shemo zdravljenja na osnovi platine ali po takšnem zdravljenju.
English: Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC).
Slovenian: Zdravilo Tecentriq je v kombinaciji z bevacizumabom, paklitakselom in karboplatinom indicirano kot prva linija zdravljenja odraslih bolnikov z razsejanim neploščatoceličnim nedrobnoceličnim rakom pljuč (NDRP).
English: (25.5%), nausea (23.5%), cough (20.8%), dyspnoea (20.5%), pyrexia (20.1%), diarrhoea (19.7%), rash (19.5%), back pain (15.3%), vomiting (15.0%), asthenia (14.5%), arthralgia (13.9%), musculoskeletal pain (13.0%), pruritus (12.6%) and urinary tract infection (11.6%).
Slovenian: Najpogostejši neželeni učinki (> 10 %) so bili utrujenost (35,9 %), zmanjšan apetit (25,5 %), navzea (23,5 %), kašelj (20,8 %), dispneja (20,5 %), zvišana telesna temperatura (20,1 %), diareja (19,7 %), izpuščaj (19,5 %), bolečina v hrbtu (15,3 %), bruhanje (15,0 %), astenija (14,5 %), artralgija (13,9 %), mišično-skeletna bolečina (13,0 %), srbenje (12,6 %) in okužba sečil (11,6 %).
English: It is used when this cancer has: spread to other parts of the body come back after previous treatment or, if you cannot receive anticancer medicine (a chemotherapy called cisplatin), and your doctor has tested your cancer and found high levels of a specific protein in your body called programmed death-ligand 1 (PD-L1).
Slovenian: Pri tem raku ga uporabljamo: če se je razširil v druge dele telesa, če se je ponovil po predhodnem zdravljenju, ali če ne morete prejemati zdravila proti raku (kemoterapevtika cisplatina) in je vaš zdravnik pri testiranju raka ugotovil, da imate v telesu visoko raven specifične beljakovine, imenovane ligand za programirano celično smrt 1 (PD-L1).
English: First-line treatment of non-small cell lung cancer
Slovenian: Prva linija zdravljenja nedrobnoceličnega raka pljuč
English: It is used when this cancer has: spread to other parts of the body come back after previous treatment - or, if you cannot receive anticancer medicine (a chemotherapy called cisplatin), and your doctor has tested your cancer and found high levels of a specific protein in your body called programmed death-ligand 1 (PD-L1).
Slovenian: Pri tem raku ga uporabljamo: - če se je razširil v druge dele telesa, - če se je ponovil po predhodnem zdravljenju, - ali če ne morete prejemati zdravila proti raku (kemoterapevtika cisplatina) in je vaš zdravnik pri testiranju raka ugotovil, da imate v telesu visoko raven specifične beljakovine, imenovane ligand za programirano celično smrt 1 (PD-L1).
English: Treatment may be resumed when symptoms are controlled by antithyroid medicinal product and thyroid function is improving
Slovenian: Zdravljenje se lahko znova začne, ko so simptomi obvladani z zdravilom za zdravljenje hipertiroze in se delovanje ščitnice izboljšuje.